What did the new achondroplasia pill trial actually find?

Infigratinib met Phase 3 growth and body-proportion endpoints, but it remains under FDA review and is not an approved treatment.

BridgeBio reports that oral infigratinib met the primary and key secondary endpoints in the Phase 3 PROPEL 3 trial. The company measured a 2.10 cm-per-year treatment effect in annualized height velocity and statistically significant improvements in body proportionality and arm span, with favorable trends in sleep apnea and ear infections. Those are trial results—not a cure claim and not proof of every long-term benefit.

The FDA has accepted the new-drug application for Priority Review with a target action date of February 4, 2027. Infigratinib is not approved for achondroplasia today; if approved, it could become the first oral therapy for children with the condition. Families should discuss the evidence, eligibility, side effects, and existing options with a specialist.